| Preview | Issue Date | Title / Name | Author(s) | Type |
| 2022 | Crescentic immunoglobulin a nephropathy with positive anti-neutrophil cytoplasmic antibodies: A rare combination | Shan, J.; Kanaan, Z.; Javaid, M. M.; Shan, Jocelyn; Javaid, Muhammad M. | Conference Paper | |
| 2022 | Doctors With Borders: The impact of international travel bans on Timorese citizens awaiting cardiac intervention | Paratz, E.; Wilson, W.; Mock, N.; Marques, D.; Kushwaha, V., et al | Conference Paper | |
| 2021 | MO01.39 Liposomal Irinotecan in Adults with Small Cell Lung Cancer who Progressed on Platinum-Based Therapy: Subgroup Analyses by Platinum Sensitivity | Spigel, David R.; Paz-Ares, Luis G.; Chen, Yuanbin; Jove, Maria; Juan-Vidal, Oscar, et al | Conference Paper | |
| 2018 | Post kidney transplantation membranoproliferative glomerulonephritis associated with light-chain paraproteinaemia | Steinberg, A.; Barraclough, N.; Hill, P.; Dwyer, K.; Goodman, D., et al | Conference Paper | |
| 2019 | Prostate cancer outcome disparity in South West Victoria | Dean, Samantha L.; Matheson, Leigh M.; Davidson, Adee J.; Grills, Richard; Kearns, Paul, et al | Conference Paper | |
| 2020 | RESILIENT part 1: Pharmacokinetics of second-line (2L) liposomal irinotecan in patients with small cell lung cancer (SCLC) | Ponce, Santiago; Brendel, K.; Spigel, David R.; Chen, Yuanbin; Jove Casulleras, M., et al | Conference Paper | |
| 2020 | RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity | Spigel, David R.; Paz-Ares, Luis G.; Chen, Yuanbin; Jove, Maria; Juan-Vidal, Oscar, et al | Conference Paper | |
| 1997 | The effect of 12 months' treatment with eicosapentaenoic acid in five children with Cystic Fibrosis | Thies, Nick H.; Thies, Nick H. | Journal Article | |
